Log In Sign up
The largest database of trusted experimental protocols

Anti cd25 apc cy7

Manufactured by Thermo Fisher Scientific
Visit Supplier

Anti-CD25 APC-Cy7 is a fluorescently-labeled monoclonal antibody that binds to the CD25 cell surface antigen. The APC-Cy7 fluorescent label allows for detection and analysis of CD25-expressing cells using flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

Anti icos pe, by BD (4 mentions) Anti cd127 fitc, by Thermo Fisher Scientific (4 mentions) Facs lsr 2 flow cytometer, by BD (4 mentions) Live dead fixable dead cell stain kit, by Thermo Fisher Scientific (4 mentions)

Spelling variants of this product

CD25-APC (58 citations) Anti-CD25-APC (39 citations) APC-Cy7 (32 citations)

4 protocols using anti cd25 apc cy7

1

Treg Characterization in Lymphoma Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 8

The inventors have analyzed the Teg numbers and the expression of ICOS on Treg in LNH samples. Fresh lymphoma cells teased from lymph nodes were collected from 45 patients with informed consent. Lymphoma samples correspond to Hodgkin disease (HD, n=11), follicular lymphoma (FL, n=13), diffuse large B cell lymphoma (DLBCL, n=10), mantle cell lymphoma (MCL, n=5) and marginal zone lymphoma (MZL, n=6). Detection of Treg cells was performed by incubation for 20 min at 4° C. with anti-ICOS-PE (Becton Dickinson™), anti-CD3-ECD, anti-CD4-Pacific Blue (Beckman Coulter®), anti-CD127 FITC, anti-CD25 APC-Cy7 and LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen™). After staining, each cell preparation was washed twice in PBS, fixed with 2% paraformaldehyde and analyzed on a FACS LSR2 flow cytometer (Becton Dickinson™). Data were analyzed using FlowJo Software (TreeStar™). Treg were increased in all lymphoma samples except HD. Most of Treg displayed an increased expression of ICOS in comparison to control lymph nodes (FIG. 8).

US09975950B2. Antibodies directed against ICOS and uses thereof (2018-05-22). INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) [FR], INSTITUT JEAN PAOLI & IRENE CALMETTES [FR], UNIVERSITE D'AIX-MARSEILLE [FR], Universite Claude Bernard-Lyon 1 [FR], Centre Leon Berard [FR]. Inventors: Julien Faget [FR], Christophe Caux [FR], Christine Menetrier-Caux [FR], Jacques Nunes [FR], Daniel Olive [FR].
+ Open protocol
+ Expand
2

Treg Characterization in Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 8

The inventors have analyzed the Teg numbers and the expression of ICOS on Treg in LNH samples. Fresh lymphoma cells teased from lymph nodes were collected from 45 patients with informed consent. Lymphoma samples correspond to Hodgkin disease (HD, n=11), follicular lymphoma (FL, n=13), diffuse large B cell lymphoma (DLBCL, n=10), mantle cell lymphoma (MCL, n=5) and marginal zone lymphoma (MZL, n=6). Detection of Treg cells was performed by incubation for 20 min at 4° C. with anti-ICOS-PE (Becton Dickinson™), anti-CD3-ECD, anti-CD4-Pacific Blue (Beckman Coulter®), anti-CD127 FITC, anti-CD25 APC-Cy7 and LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen™). After staining, each cell preparation was washed twice in PBS, fixed with 2% paraformaldehyde and analyzed on a FACS LSR2 flow cytometer (Becton Dickinson™). Data were analyzed using FlowJo Software (TreeStar™). Treg were increased in all lymphoma samples except HD. Most of Treg displayed an increased expression of ICOS in comparison to control lymph nodes (FIG. 8).

US10745482B2. Antibodies directed against ICOS and uses thereof (2020-08-18). INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) [FR], INSTITUT JEAN PAOLI & IRENE CALMETTES [FR], UNIVERSITE D'AIX-MARSEILLE [FR], Universite Claude Bernard—Lyon 1 [FR], Centre Leon Berard [FR]. Inventors: Julien Faget [FR], Christophe Caux [FR], Christine Menetrier-Caux [FR], Jacques Nunes [FR], Daniel Olive [FR].
+ Open protocol
+ Expand
3

Treg Profiling in Lymphoma Subtypes

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 8

The inventors have analyzed the Treg numbers and the expression of ICOS on Treg in LNH samples. Fresh lymphoma cells leased from lymph nodes were collected from 45 patients with informed consent. Lymphoma samples correspond to Hodgkin disease (HD, n=11), follicular lymphoma (FL, n=13), diffuse large B cell lymphoma (DLBCL, n=10), mantle cell lymphoma (MCL, n=5) and marginal zone lymphoma (MZL, n=6). Detection of Treg cells was performed by incubation for 20 min at 4° C. with anti-ICOS-PE (Becton Dickinson™), anti-CD3-ECD, anti-CD4-Pacific Blue (Beckman Coulter®), anti-CD127 FITC, anti-CD25 APC-Cy7 and LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen™). After staining, each cell preparation was washed twice in PBS, fixed with 2% paraformaldehyde and analyzed on a FACS LSR2 flow cytometer (Becton Dickinson™). Data were analyzed using FlowJo Software (TreeStar™). Treg were increased in all lymphoma samples except HD. Most of Treg displayed an increased expression of ICOS in comparison to control lymph nodes (FIG. 8).

US10633446B2. Antibodies directed against ICOS and uses thereof (2020-04-28). INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) [FR], INSTITUT JEAN PAOLI & IRENE CALMETTES [FR], UNIVERSITE D'AIX-MARSEILLE [FR], Universite Claude Bernard-Lyon 1 [FR], Centre Leon Berard [FR]. Inventors: Julien Faget [FR], Christophe Caux [FR], Christine Menetrier-Caux [FR], Jacques Nunes [FR], Daniel Olive [FR].
+ Open protocol
+ Expand
4

Treg Analysis in Lymphoma Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 8

The inventors have analyzed the Teg numbers and the expression of ICOS on Treg in LNH samples. Fresh lymphoma cells leased from lymph nodes were collected from 45 patients with informed consent. Lymphoma samples correspond to Hodgkin disease (HD, n=11), follicular lymphoma (FL, n=13), diffuse large B cell lymphoma (DLBCL, n=10), mantle cell lymphoma (MCL, n=5) and marginal zone lymphoma (MZL, n=6). Detection of Treg cells was performed by incubation for 20 min at 4° C. with anti-ICOS-PE (Becton Dickinson™), anti-CD3-ECD, anti-CD4-Pacific Blue (Beckman Coulter®), anti-CD127 FITC, anti-CD25 APC-Cy7 and LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen™). After staining, each cell preparation was washed twice in PBS, fixed with 2% paraformaldehyde and analyzed on a FACS LSR2 flow cytometer (Becton Dickinson™). Data were analyzed using FlowJo Software (TreeStar™). Treg were increased in all lymphoma samples except HD. Most of Treg displayed an increased expression of ICOS in comparison to control lymph nodes (FIG. 8).

US11180556B2. Antibodies directed against ICOS and uses thereof (2021-11-23). INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) [FR], INSTITUT JEAN PAOLI & IRENE CALMETTES [FR], UNIVERSITE D'AIX-MARSEILLE [FR], Universite Claude Bernard—Lyon 1 [FR], Centre Leon Berard [FR]. Inventors: Julien Faget [FR], Christophe Caux [FR], Christine Menetrier-Caux [FR], Jacques Nunes [FR], Daniel Olive [FR].
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!